Piper Jaffray analyst Christopher Raymond keeps a Neutral rating on Amag Pharmaceuticals after the company's disclosure of a delay to Vyleesi timelines as a result of an FDA request for additional clinical safety data. The analyst says that while management has touted this drug's potential as a major contributor, he remains "skeptical," given the uncertainty around the female sexual dysfunction market and the drug's side effect and convenience profile. Raymond is keeping Vyleesi out of his model and remains "cautious" on Amag shares with a $20 price target.